(Q35814359)

10 August 2017

1 reference

title

Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections (English)

1 reference

10 August 2017

1 reference

1

Caroline M Perry

1 reference

10 August 2017

2

Lesley J Scott

1 reference

10 August 2017

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

64

1 reference

10 August 2017

issue

13

1 reference

10 August 2017

page(s)

1433-1464

1 reference

Review of consensus reports on management of acute otitis media

10 August 2017

cites work

1 reference

12 December 2020

Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997)

1 reference

12 December 2020

Efficacy and safety of cefdinir in the treatment of maxillary sinusitis.

1 reference

12 December 2020

In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, a

1 reference

12 December 2020

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins

1 reference

12 December 2020

Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients

1 reference

12 December 2020

Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice.

1 reference

12 December 2020

Distribution of cefdinir, a third generation cephalosporin antibiotic, in serum and pulmonary compartments

1 reference

12 December 2020

Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program

1 reference

12 December 2020

Comparative kill and growth rates determined with cefdinir and cefaclor and with Streptococcus pneumoniae and beta-lactamase-producing Haemophilus influenzae

1 reference

12 December 2020

Morphological alterations of Staphylococcus aureus and Streptococcus pyogenes exposed to cefdinir, a new oral broad-spectrum cephalosporin

1 reference

12 December 2020

Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829

1 reference

12 December 2020

Antimicrobial resistance with Streptococcus pneumoniae in the United States.

1 reference

12 December 2020

Acute otitis media in pediatric medicine: current issues in epidemiology, diagnosis, and management

1 reference

12 December 2020

Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin

1 reference

12 December 2020

In vitro antibacterial activity of FK041, a new orally active cephalosporin.

1 reference

12 December 2020

Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats.

1 reference

12 December 2020

Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil

1 reference

12 December 2020

Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin

1 reference

12 December 2020

Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group.

1 reference

12 December 2020

Patient, physician, and nurse satisfaction with antibiotics

1 reference

12 December 2020

Effects of organic anion, organic cation, and dipeptide transport inhibitors on cefdinir in the isolated perfused rat kidney

1 reference

12 December 2020

Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group

1 reference

12 December 2020

Fundamental basis for rational therapeutics in acute otitis media

1 reference

12 December 2020

Comparative safety and efficacy of cefdinir vs amoxicillin/clavulanate for treatment of suppurative acute otitis media in children

1 reference

12 December 2020

Effects of various test media on the activities of 21 antimicrobial agents against Haemophilus influenzae

1 reference

12 December 2020

The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections

1 reference

12 December 2020

Cefdinir: in vitro activity study and effect of human serum.

1 reference

12 December 2020

In vivo antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin

1 reference

12 December 2020

Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin

1 reference

12 December 2020

Cefdinir: an expanded-spectrum oral cephalosporin

1 reference

12 December 2020

Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients

1 reference

12 December 2020

Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media

1 reference

12 December 2020

In vitro activity of faropenem against 5460 clinical bacterial isolates from Europe

1 reference

12 December 2020

Antimicrobial resistance with Streptococcus pneumoniae: much ado about nothing?

1 reference

12 December 2020

Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.

1 reference

12 December 2020

Failure of penicillin to eradicate group A beta-hemolytic streptococci tonsillitis: causes and management

1 reference

12 December 2020

In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.

1 reference

12 December 2020

International study comparing cefdinir and cefuroxime axetil in the treatment of patients with acute exacerbation of chronic bronchitis.

1 reference

12 December 2020

Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice

1 reference

12 December 2020

In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients.

1 reference

12 December 2020

Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States

1 reference

12 December 2020

Antibacterial therapy for acute group a streptococcal pharyngotonsillitis: short-course versus traditional 10-day oral regimens

1 reference

12 December 2020

Five-day cefdinir treatment for streptococcal pharyngitis. Cefdinir Pharyngitis Study Group

1 reference

12 December 2020

Activity of oral agents against pediatric isolates of Streptococcus pneumoniae

1 reference

12 December 2020

In vitro and In vivo activities of LB 10827, a new oral cephalosporin, against respiratory pathogens

1 reference

12 December 2020

Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates

1 reference

12 December 2020

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem.

1 reference

12 December 2020

A study of 5-day cefdinir treatment for streptococcal pharyngitis in children. Cefdinir Pediatric Pharyngitis Study Group

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections

1 reference

12 December 2020

Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of oral cephalosporins as critical factors in choice of antibiotics

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

12 December 2020

Comparison of cefdinir and penicillin for the treatment of pediatric streptococcal pharyngitis

1 reference

12 December 2020

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

12 December 2020

Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis. Cefdinir Sinusitis Study Group

1 reference

12 December 2020

Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia.

1 reference

12 December 2020

In vitro antibacterial activity of FK482, a new orally active cephalosporin

1 reference

12 December 2020

Treatment of acute otitis media consensus recommendations

1 reference

12 December 2020

Antimicrobial activities of cefditoren against respiratory pathogens isolated from children in Japan.

1 reference

12 December 2020

Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases

1 reference

12 December 2020

Bactericidal activity and postantibiotic effect of cefdinir (Cl 983, FK 482) against selected pathogens

1 reference

12 December 2020

The sensitivity of clinical bacteria isolated in Scotland to the oral cephalosporin, cefdinir.

1 reference

12 December 2020

The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents

1 reference

12 December 2020

The in-vitro activity of cefdinir (FK482), a new oral cephalosporin

1 reference

12 December 2020

Stability of cefdinir (C1-983, FK482) to extended-spectrum plasmid-mediated beta-lactamases.

1 reference

12 December 2020

Controversies in the medical management of persistent and recurrent acute otitis media. Recommendations of a clinical advisory committee.

1 reference

12 December 2020

Comparison of cefdinir and penicillin V in the treatment of pediatric streptococcal tonsillopharyngitis

1 reference

12 December 2020

The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections

1 reference

12 December 2020

Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States

1 reference

12 December 2020

In vivo antibacterial activity of FK041, a new orally active cephalosporin

1 reference

12 December 2020

Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98)

1 reference

12 December 2020

Prescribing antimicrobial agents for treatment of acute otitis media

1 reference

12 December 2020

Molecular characterization of the BRO beta-lactamase of Moraxella (Branhamella) catarrhalis

1 reference

12 December 2020

Antistaphylococcal activity of cefdinir, a new oral third-generation cephalosporin, alone and in combination with other antibiotics, at supra- and sub-MIC levels.

1 reference

12 December 2020

1 reference

12 December 2020

Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management.

1 reference

12 December 2020

Cefdinir vs. amoxicillin/clavulanic acid in the treatment of suppurative acute otitis media in children

1 reference

12 December 2020

Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial a

1 reference

12 December 2020

Interaction of cefdinir with beta-lactamases.

1 reference

12 December 2020

Comparison of cefdinir and penicillin for the treatment of streptococcal pharyngitis. Cefdinir Pharyngitis Study Group

1 reference

12 December 2020

Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses

1 reference

12 December 2020

In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity

1 reference

12 December 2020

In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolides

1 reference

12 December 2020

In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998

1 reference

12 December 2020

Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002)

1 reference

12 December 2020

Cefdinir-induced modification of the susceptibility of bacteria to the antibacterial activity of human serum and polymorphonuclear neutrophils

1 reference

12 December 2020

Compliance issues related to the selection of antibiotic suspensions for children

1 reference

12 December 2020

Activity of cefditoren against respiratory pathogens

1 reference

12 December 2020

Formulations of antibiotics for children in primary care: effects on compliance and efficacy

1 reference

12 December 2020

In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.

1 reference

12 December 2020

Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000-2001: a comparison with other beta-lactam agents

1 reference

12 December 2020

Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis

1 reference

12 December 2020

Five-day cefdinir course vs. ten-day cefprozil course for treatment of acute otitis media

1 reference

12 December 2020

Beta-lactamase-mediated resistance and opportunities for its control

1 reference

12 December 2020

Antibiotic treatment for acute otitis media

1 reference

12 December 2020

Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group.

1 reference

12 December 2020

Impairment of cefdinir absorption by iron ion

1 reference

12 December 2020

A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis

1 reference

12 December 2020

Resistance among Streptococcus pneumoniae: Implications for drug selection

1 reference

12 December 2020

treatment and prevention of otitis media

1 reference

12 December 2020

Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan.

1 reference

12 December 2020

Duration of therapy for acute otitis media

1 reference

12 December 2020

In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenem

1 reference

12 December 2020

Short-Course antimicrobial therapy for upper respiratory tract infections

1 reference

12 December 2020

10.2165/00003495-200464130-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1013821422

0 references

1 reference